Overview

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Status:
Terminated

Trial end date:
2014-06-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Albumin-Bound Paclitaxel
Docetaxel
Paclitaxel